1,214 results on '"Boissel, Nicolas"'
Search Results
2. Life-threatening complications and intensive care unit management in patients treated with blinatumomab for B-cell acute lymphoblastic leukemia
3. Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22+ Philadelphia Chromosome–Negative B-Cell Precursor Acute Lymphoblastic Leukemia
4. Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3.
5. Early lymphocyte reconstitution and viral infections in adolescents and adults transplanted for sickle cell disease
6. Factors associated with the collection of isolated immature oocytes during ovarian tissue cryopreservation
7. NGS-based stratification refines the risk stratification in T-ALL and identifies a very-high-risk subgroup of patients
8. Genomic imbalance analysis provides new insight into prognostic factors in adult and pediatric T-ALL
9. Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia
10. TREC mediated oncogenesis in human immature T lymphoid malignancies preferentially involves ZFP36L2
11. Harnessing the MYB-dependent TAL1 5’super-enhancer for targeted therapy in T-ALL
12. Real-world use of blinatumomab in adult patients with B-cell acute lymphoblastic leukemia in clinical practice: results from the NEUF study
13. Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study
14. Benefits of dexamethasone on early outcomes in patients with acute myeloid leukemia with hyperleukocytosis: a propensity score matched analysis
15. Genetic alterations and MRD refine risk assessment for KMT2A-rearranged B-cell precursor ALL in adults: a GRAALL study
16. Combining blinatumomab and donor lymphocyte infusion in B-ALL patients relapsing after allogeneic hematopoietic cell transplantation: a study of the SFGM-TC
17. IL-7 receptor expression is frequent in T-cell acute lymphoblastic leukemia and predicts sensitivity to JAK inhibition
18. Oncogenetic landscape of T-cell lymphoblastic lymphomas compared to T-cell acute lymphoblastic leukemia
19. Bridging Chemotherapy: Adult Acute Lymphoblastic Leukaemia
20. Long-term survival outcomes of patients (pts) with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-3.
21. UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial
22. Concurrent CDX2 cis-deregulation and UBTF::ATXN7L3 fusion define a novel high-risk subtype of B-cell ALL
23. The use of ICU resources in CAR-T cell recipients: a hospital-wide study
24. Prognostic of Core Binding Factor (CBF) Acute Myeloid Leukemia With Complex Karyotype
25. Immunotherapies in acute leukemia
26. Inotuzumab ozogamicin in adult acute lymphoblastic leukemia: Development, current status, and future directions.
27. Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia
28. Early detection of WT1 measurable residual disease identifies high-risk patients, independent of transplantation in AML
29. Laboratory tests for investigating anemia: From an expert system to artificial intelligence
30. DESCAR-T, le registre national des patients traités par CAR-T Cells
31. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
32. A multiparametric niche-like drug screening platform in acute myeloid leukemia
33. Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study
34. Transplantation of cryopreserved ovarian tissue in a series of 285 women: a review of five leading European centers
35. COVID19 and acute lymphoblastic leukemias of children and adolescents: Updated recommendations (Version 2) of the Leukemia Committee of the French Society for the fight against Cancers and leukemias in children and adolescents (SFCE)
36. Efficacy and tolerance of brexucabtagene autoleucel in adults with R/R B-ALL: a GRAALL study from the DESCAR-T registry
37. LAL chez l’adulte : apport et limite de la prise en charge pédiatrique
38. A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia
39. A transcriptomic continuum of differentiation arrest identifies myeloid interface acute leukemias with poor prognosis
40. Clonal dominance is an adverse prognostic factor in acute myeloid leukemia treated with intensive chemotherapy
41. COVID-19 and acute lymphoblastic leukemias of children and adolescents: First recommendations of the Leukemia committee of the French Society for the fight against Cancers and Leukemias in children and adolescents (SFCE)
42. Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results
43. EHA evaluation of the ESMO—Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies
44. Management of ALL in Adults: 2023 ELN Recommendations from a European Expert Panel
45. Diagnosis, Prognostic Factors and Assessment of ALL in Adults: 2023 ELN Recommendations from a European Expert Panel
46. Supplementary Figure S1 from PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
47. Supplementary Table S2 from PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
48. Data from PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
49. Should patients with Ph-negative acute lymphoblastic leukaemia who reach minimal residual disease negativity have HSCT?
50. Clinico-biological features of T-cell acute lymphoblastic leukemia with fusion proteins
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.